About GENBLE

Genble Corp provides research and development services in the biotechnology, dental, medical and pharmaceutical fields.

A Brief Introduction

The vision of Genble Biotech is to enable the humanity to take charge of its own health. To achieve this vision, the Company aims to establish new health indices, which provide accurate and reliable health information for doctors and patients, to lay the foundation to detect, prevent, and treat major diseases, and to develop the relevant high quality products and services. We will apply this concept to the most threatening diseases such as cancers and the most intimate disease of humans, such as oral diseases.

Detection, prevention and treatment of cancers
The current cancer market is mainly focused on the treatment of cancer patients. However, cancer prevention is more effective; the market potential is much greater. This is because a much larger population requires cancer prevention drugs for a longer period of time.
The major obstacles in the cancer field may include: how to identify the cancer-prone population from the general population, how to prevent cancers from occurrence, and how to improve the efficacy of chemotherapy. Genble Biotech has developed IROSS® technology which can provide effective solutions and products to overcome the problems.
Using the IROSS® technology, we have developed three categories of products: (1) SOOS-1, a drug candidate to inhibit drug resistance of tumor cells; (2) ASOS-1 diagnosis kit to assess the potential for mutation; (2) SOOS-2, a healthcare product to reduce the potential for cancer. These three products are being commercialized.

The ASOS-1 diagnosis kit can predict the potential for gene mutation; thus it is expected to become a new health standard in the cancer field.

OIKE® - A new oral technology for diagnosis and treatment of oral diseases
90% of the population in China has various degrees of oral diseases, including periodontitis, tooth decay, and recurrent oral ulcers.
Genble Biotech has developed an innovative oral biotechnology OIKE®. OIKE® provides a new set of solutions and standards for prevention and treatment of oral diseases. We have developed a new diagnosis system that can accurately assess the degree of oral inflammation and a new set of devices that can prevent and treat oral diseases. Currently, we are introducing these innovative products and services to the market.

The diagnosis system is able to quantify oral health and is expected to become a new standard for oral health.

Corporate Plan

Development of new standards is an important symbol of first-class enterprise. We develop the platform technology for two new health indexes: gene mutation potential and oral inflammation index. Through the health indexes, we introduce our new products and services into the market gradually. These two areas can complement each other: one has a greater market potential; another can generate a quicker result. Because of the complementarities of the two areas, our Company can grow quickly in a steady fashion.

Our vision

To enable the humanity to take charge of its own health.

Our mission

To take the lead in frontier technology for preventing and treating cancer and oral disease.

Corporate Culture
Genble Biotech is an ideal place to pursue dreams, advocate for justice and share the fruits of scientific discovery and technological innovation. Genble is a great stage for all the employees to exhibit talents, create innovation and fulfill ambitions.
Genble"s vision is to enable the humanity to take charge of its own health, to advocate for scientific decision and rational consumption, and to provide reliable, high-quality, high-tech products and services for our consumers.
Genble Biotech is highly innovative and progressive; the Company is always exploring in the scientific frontiers and looking for reliable, practical and dignified solutions for human health.
The development and growth of Genble Biotech is based on creating tangible benefits for human health, based on productive cooperation of our staff, and based on scientific management and decision making.
The track record of Genble Biotech is full of constant self-challenging and the courage to reach new heights; it is an environment full of personal touch, positive interactions and harmonious collaborations. The Company is a magnet for efficiency, quality, competence and enthusiasm to share.

Genble: maximizing the potential for a shinier life!

Technology Platform

Genble Bioteh has developed two innovative platforms: a new drug discovery technology IROSS® and a novel oral technology OIKE®. These two platforms can be used to develop a series of useful products and services.

A new drug discovery technology IROSS®
While exploring in the frontiers of molecular biology, we developed a set of new cell-based drug screening and identification systems, which is called “Intracellular reactive oxygen species scavenging” (IROSS®). IROSS® is an internationally patented technology.
IROSS® technology uses a proprietary reporter gene, which can accurately reflect intracellular oxidative stress and thus identify effective anti-oxidative drug candidates under laboratory conditions. Therefore, IROSS® can examine intracellular efficacy rather than the chemical properties of the test compound.
IROSS® technology is a major breakthrough in term of the technology and theory in the field of “oxidative stress”, because it has made an important leap from detection of chemical properties to direct determination of intracellular efficacy of a drug candidate. Thus, it can greatly enhance the efficiency and accuracy of drug screening.
Using IROSS® technology, we identified some active ingredients, which can effectively scavenge intracellular oxidative stress. They are called “Scavengers of oxidative stress” (SOOS). The SOOS compounds that we identified can inhibit the mutation rate by up to 100 times. One of these ingredients is termed SOOS-1, which can inhibit the drug-resistance of tumor cells; it will be developed as a new drug for cancer chemotherapy. Another is termed SOOS-2, which can inhibit in vivo gene mutation and will be developed as a product for cancer prevention.

We also developed a diagnosis kit for ASOS-1. We found that gene mutation is closely linked to ASOS-1. The kit can assess the potential for gene mutation, which is useful for cancer prevention.

A novel oral technology OIKE®
Our current oral hygiene habits are usually limited to cleaning of the teeth, which is not enough for oral health. Studies show that 90% of Chinese population has various degrees of oral diseases, including periodontitis, tooth decay, recurrent oral ulcers, and bad breath, snoring and other oral problems.
We have developed a new oral technology OIKE®. This technology contains a testing system for oral inflammatory index (OII) and a set of new oral cleaning devices. OII can be used to accurately evaluate oral health and provide a quantitative indicator for oral disease. The oral cleaning devices can be used to help prevent oral diseases.
OIKE® can diagnose and cure oral diseases for our consumers; it can also improve dental, oral and physical health. OIKE® will establish a new set of health standards for oral healthcare, oral disease prevention and treatment. The new oral technology OIKE® will lead to a new level of human health.